Fate Therapeutics Inc. has granted non-qualified stock options to one newly hired non-executive employee for the purchase of 48,000 shares at an exercise price of $0.98 per share, reflecting the closing price on December 31, 2025. Additionally, restricted stock units (RSUs) totaling 79,400 shares were awarded to four newly hired non-executive employees. The stock options vest over four years, with 25% vesting after one year and the remainder vesting in equal monthly installments over the following three years. The RSUs also vest over four years, with 25% vesting on each anniversary of the grant date. Vesting is contingent on continued employment with the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620117-en) on January 05, 2026, and is solely responsible for the information contained therein.
Comments